{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:03:44Z","timestamp":1794848624583,"version":"4.9.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000009519","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T15:54:31Z","timestamp":1514390071000},"page":"e9519","source":"Crossref","is-referenced-by-count":8,"title":["Pembrolizumab for recurrent\/metastatic head and neck squamous cell carcinoma in an Asian population"],"prefix":"10.1097","volume":"96","author":[{"given":"Wen-Chun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pen-Yuan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Mu-Hsin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muh-Hwa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-67-20210226","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1726-4901(10)70064-2","article-title":"Cetuximab-based therapy in recurrent\/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular","volume":"73","author":"Chang","year":"2010","journal-title":"J Chin Med Assoc"},{"key":"R2-67-20210226","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-67-20210226","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.ejca.2004.05.019","article-title":"Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer","volume":"40","author":"Guardiola","year":"2004","journal-title":"Eur J Cancer"},{"key":"R4-67-20210226","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(15)70124-5","article-title":"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial","volume":"16","author":"Machiels","year":"2015","journal-title":"Lancet Oncol"},{"key":"R5-67-20210226","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","article-title":"Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study","volume":"10","author":"Forastiere","year":"1992","journal-title":"J Clin Oncol"},{"key":"R6-67-20210226","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase Ib trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"R7-67-20210226","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-67-20210226","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13000-016-0545-8","article-title":"Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma","volume":"11","author":"Rebelatto","year":"2016","journal-title":"Diagn Pathol"},{"key":"R9-67-20210226","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/psp4.12130","article-title":"Translational pharmacokinetic\/pharmacodynamic modeling of tumor growth inhibition supports dose-range selection of the anti-PD-1 antibody pembrolizumab","volume":"6","author":"Lindauer","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R10-67-20210226","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/psp4.12139","article-title":"Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors","volume":"6","author":"Ahamadi","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R11-67-20210226","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-67-20210226","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"R13-67-20210226","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R14-67-20210226","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1758-3284-2-15","article-title":"Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)","volume":"2","author":"Dayyani","year":"2010","journal-title":"Head Neck Oncol"},{"key":"R15-67-20210226","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","article-title":"Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"R16-67-20210226","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0714.2011.01046.x","article-title":"Role of human papillomavirus infection in carcinogenesis of oral squamous cell carcinoma with evidences of prognostic association","volume":"41","author":"Chen","year":"2012","journal-title":"J Oral Pathol Med"},{"key":"R17-67-20210226","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"R18-67-20210226","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"R19-67-20210226","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2016","journal-title":"J Clin Oncol"},{"key":"R20-67-20210226","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","volume":"35","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R21-67-20210226","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"R22-67-20210226","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"R23-67-20210226","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"R24-67-20210226","doi-asserted-by":"crossref","first-page":"857519","DOI":"10.1155\/2013\/857519","article-title":"Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica"},{"key":"R25-67-20210226","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/psp4.12132","article-title":"Using model-based \u201clearn and confirm\u201d to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial","volume":"6","author":"Elassaiss-Schaap","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R26-67-20210226","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/psp4.12140","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma","volume":"6","author":"Chatterjee","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R27-67-20210226","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.2147\/OTT.S112472","article-title":"A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin","volume":"9","author":"Xu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R28-67-20210226","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/bjh.13920","article-title":"Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma","volume":"176","author":"Kwong","year":"2017","journal-title":"Br J Haematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:50:40Z","timestamp":1620960640000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712290-00067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":28,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009519","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}